AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 295: H113-H122, 2008. First published May 9, 2008; doi:10.1152/ajpheart.00172.2008
0363-6135/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/1/H113    most recent
00172.2008v2
00172.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Mazza, R.
Right arrow Articles by Mahata, S. K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mazza, R.
Right arrow Articles by Mahata, S. K.

Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart

Rosa Mazza,1,* Alfonsina Gattuso,1,* Cinzia Mannarino,1 Bhawanjit K. Brar,2 Sandra Francesca Barbieri,1 Bruno Tota,1 and Sushil K. Mahata2

1Department of Cell Biology, University of Calabria, Arcavacata di Rende, Italy; and 2Department of Medicine, University of California and Veterans Affairs San Diego Healthcare System, San Diego, California

Submitted 18 February 2008 ; accepted in final form 2 May 2008

The catecholamine release-inhibitory catestatin [Cts; human chromogranin (Cg) A352-372, bovine CgA344-364] is a vasoreactive and anti-hypertensive peptide derived from CgA. Using the isolated avascular frog heart as a bioassay, in which the interactions between the endocardial endothelium and the subjacent myocardium can be studied without the confounding effects of the vascular endothelium, we tested the direct cardiotropic effects of bovine Cts and its interaction with β-adrenergic (isoproterenol, ISO) and endothelin-1 (ET-1) signaling. Cts dose-dependently decreased stroke volume and stroke work, with a threshold concentration of 11 nM, approaching the in vivo level of the peptide. Cts reduced contractility by inhibiting phosphorylation of phospholamban (PLN). Furthermore, the Cts effect was abolished by pretreatment with either nitric oxide synthase (NG-monomethyl-L-arginine) or guanylate cyclase (ODQ) inhibitors, or an ETB receptor (ETBR) antagonist (BQ-788). Cts also noncompetitively inhibited the positive inotropic action of ISO. In addition, Cts inhibited the positive inotropic effect of ET-1, mediated by ETA receptors, and did not alter the negative inotropic ET-1 influence mediated by ETBR. Cts action through ETBR was further suggested when, in the presence of BQ-788, Cts failed to inhibit the positive inotropism of both ISO and ET-1 stimulation and PLN phosphorylation. We concluded that the cardiotropic actions of Cts, including the β-adrenergic and ET-1 antagonistic effects, support a novel role of this peptide as an autocrine-paracrine modulator of cardiac function, particularly when the stressed heart becomes a preferential target of both adrenergic and ET-1 stimuli.

chromogranin A; myocardial contractility; inotropic agents; avascular heart; endocardial endothelium



Address for reprint requests and other correspondence: S. K. Mahata, Dept. of Medicine, Univ. of California & VA San Diego Healthcare System, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0838 (e-mail: smahata{at}ucsd.edu) or B. Tota, Department of Cell Biology, University of Calabria, 87030 Arcavacata di Rende (CS), Italy (e-mail: tota{at}unical.it)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.